LinusBio is at the forefront of precision exposome medicine, utilizing a unique temporal exposomic platform that analyzes an individual's biological response to environmental exposures over time. By employing a strand of hair, the company conducts temporal exposomic sequencing, which allows for the mapping of molecular dynamics in human physiology in a time-dependent manner. This innovative approach generates data comparable to over 500 liquid biopsies, enabling the identification of novel biomarkers for various health conditions, including Autism Spectrum Disorder (ASD), gastrointestinal disorders, and other complex diseases that have historically lacked reliable biological tests for diagnosis and monitoring.

One of LinusBio's flagship products is StrandDx™ASD, a non-invasive diagnostic aid for Autism Spectrum Disorder, which has achieved FDA Breakthrough Designation due to its high accuracy rates of 80% to 90%. This test is notable for being the first objective biomarker test for ASD, capable of detection as early as one month of age. LinusBio's commitment to advancing precision medicine extends beyond ASD, as the company is actively developing a pipeline of novel biomarkers for other conditions, such as ADHD and ALS, aiming to enhance diagnostic capabilities and treatment strategies across a wide range of health issues.

United States

Linus Biotechnology is a patient-centric, breakthrough science, precision exposome medicine company. Our program pipeline comprises precision exposome medicine biomarkers and target discovery across disease domains for which historically no molecular endpoints have been available in medical practice or for clinical trials, including CNS (autism spectrum disorder, amyotrophic lateral sclerosis), gastroenterology (inflammatory bowel disease), renal disease and oncology.

LinusBio

Company Details